 Shares of Eagle Pharmaceuticals NASDAQ:EGRX were flat in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share decreased 32.14 year over year to 0.57, which beat the estimate of 0.26.Revenue of 41,938,000 decreased by 26.04 year over year, which missed the estimate of 42,280,000.Outlook Earnings guidance hasnt been issued by the company for now.Eagle Pharmaceuticals hasnt issued any revenue guidance for the time being.Conference Call Details Date: Aug 10, 2020View more earnings on EGRXTime: 08:30 AMET Webcast URL: Companys 52-week high was at 64.94Companys 52-week low was at 33.80Price action over last quarter: down 13.26Company Description Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development, and under review for approval by the Food and Drug Administration.See more from Benzinga Earnings Scheduled For August 10, 2020C 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 